- Conditions
- Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
- Interventions
- Midostaurin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Berkeley, California • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced May 21, 2026, 8:09 PM EDT